A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

December 11, 2021

Study Completion Date

December 21, 2021

Conditions

Gastroesophagus Reflux Disease

Interventions

DRUG

AD-213-A

1 tablet administered before the breakfast during 5 days

DRUG

AD-2131

1 tablet administered before the breakfast during 5 days

Trial Locations (1)

Kyungpook National University Hospital, Daegu

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY

NCT04690868 - A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131 | Biotech Hunter | Biotech Hunter